aripiprazole lauroxil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychotropics, phenylpiperazine derivatives 5052 1259305-29-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aripiprazole lauroxil
  • aristada
  • RDC-3317
prodrug of aripiprazole, following intramuscular injection is converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole which is then hydrolyzed to aripiprazole
  • Molecular weight: 660.72
  • Formula: C36H51Cl2N3O4
  • CLOGP: 10.80
  • LIPINSKI: 2
  • HAC: 7
  • HDO: 0
  • TPSA: 62.32
  • ALOGS: -6.44
  • ROTB: 20

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 5, 2015 FDA ALKERMES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site pain 243.50 48.81 104 1610 107048 46577300
Injection site mass 190.27 48.81 53 1661 14987 46669361
Needle issue 144.12 48.81 35 1679 5769 46678579
Off label use 123.41 48.81 105 1609 379736 46304612
Hallucination, auditory 122.70 48.81 35 1679 10721 46673627
Injection site induration 99.85 48.81 28 1686 8051 46676297
Therapeutic response shortened 97.25 48.81 25 1689 5174 46679174
Weight increased 84.67 48.81 60 1654 164413 46519935
Product administered at inappropriate site 78.06 48.81 18 1696 2365 46681983
Inappropriate schedule of product administration 56.34 48.81 33 1681 64980 46619368

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site pain 284.69 60.80 96 1785 30214 29920383
Product administered at inappropriate site 187.21 60.80 38 1843 1597 29949000
Hallucination, auditory 180.09 60.80 52 1829 9737 29940860
Therapeutic response shortened 147.10 60.80 36 1845 3564 29947033
Needle issue 115.25 60.80 30 1851 3802 29946795
Off label use 84.57 60.80 90 1791 249200 29701397
Injection site mass 72.13 60.80 22 1859 4931 29945666
Weight increased 61.76 60.80 45 1836 74868 29875729

Pharmacologic Action:

SourceCodeDescription
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35941 serotonergic agonists
CHEBI has role CHEBI:37955 h1-receptor blockers
CHEBI has role CHEBI:50266 prodrugs
CHEBI has role CHEBI:65191 atypical antipsychotics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.84 Basic
pKa2 0.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR PARTIAL AGONIST Ki 9.47 DRUG LABEL DRUG LABEL
5-hydroxytryptamine receptor 1A GPCR PARTIAL AGONIST Ki 8.77 DRUG LABEL DRUG LABEL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.47 DRUG LABEL DRUG LABEL
D(3) dopamine receptor GPCR Ki 9.10 DRUG LABEL
D(4) dopamine receptor GPCR Ki 7.36 DRUG LABEL
5-hydroxytryptamine receptor 2C GPCR Ki 7.82 DRUG LABEL
5-hydroxytryptamine receptor 7 GPCR Ki 7.41 DRUG LABEL
Histamine H1 receptor GPCR Ki 7.21 DRUG LABEL
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 7.20 IUPHAR
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 6.10 IUPHAR
5-hydroxytryptamine receptor 2A GPCR AGONIST Ki 7.70 IUPHAR
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 IUPHAR
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 7.80 IUPHAR
D(2) dopamine receptor GPCR AGONIST Ki 9.70 IUPHAR

External reference:

IDSource
B786J7A343 UNII
D10364 KEGG_DRUG
4034891 VANDF
C4056439 UMLSCUI
CHEBI:90930 CHEBI
CHEMBL2219425 ChEMBL_ID
DB14185 DRUGBANK_ID
49831411 PUBCHEM_CID
C000603935 MESH_SUPPLEMENTAL_RECORD_UI
1673265 RXNORM
236432 MMSL
31226 MMSL
016489 NDDF
017628 NDDF
715182007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ARISTADA HUMAN PRESCRIPTION DRUG LABEL 1 65757-401 INJECTION, SUSPENSION, EXTENDED RELEASE 441 mg INTRAMUSCULAR NDA 29 sections
ARISTADA HUMAN PRESCRIPTION DRUG LABEL 1 65757-402 INJECTION, SUSPENSION, EXTENDED RELEASE 662 mg INTRAMUSCULAR NDA 29 sections
ARISTADA HUMAN PRESCRIPTION DRUG LABEL 1 65757-403 INJECTION, SUSPENSION, EXTENDED RELEASE 882 mg INTRAMUSCULAR NDA 29 sections
ARISTADA HUMAN PRESCRIPTION DRUG LABEL 1 65757-404 INJECTION, SUSPENSION, EXTENDED RELEASE 1064 mg INTRAMUSCULAR NDA 29 sections
ARISTADA INITIO HUMAN PRESCRIPTION DRUG LABEL 1 65757-500 INJECTION, SUSPENSION, EXTENDED RELEASE 675 mg INTRAMUSCULAR NDA 29 sections